2026 · 2nd Quarter (Apr 1 - June 30)

INCYTE CORPORATION

Filed by INCYTE CORPORATION.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: Not reported
Expenses: $750,000.00
Registrant: INCYTE CORPORATION
Client: INCYTE CORPORATION
Filing UUID: cf45130f-a434-47e4-aecc-79818a163ea1
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology

Literal federal measure citations: H.R. 946, S. 1862, H. Res. 1331, S. 2658

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.